56th Annual Symposium of the SSIEM: APR Will Introduce Its Innovative Phe-Free Medical Food for PKU Management Together with New Original Scientific Data
APR Applied Pharma Research sa (“APR”), the Swiss independent developer of science driven and patent protected healthcare products, is proud to announce it will take part to the forthcoming Annual Symposium of the SSIEM (Society for the Study of Inborn Errors of Metabolism), which will be held in Athens on September 4th-7th.
This international congress, attended by academic leaders, clinicians and research scientists from leading Universities and Institutes, will be the showcase for presenting officially the company innovative Phenylalanine (Phe)-free medical food for Phenylketonuria (PKU) dietary management, powered by APR patented Physiomimic™ Technology.
In the occasion of the congress, APR will sponsor the satellite symposium “Physiological Absorption of amino acids: rationale and expected benefits” (Thursday 6th Sept from 7.30 to 8.30 am – Mitropoulos Hall), where international experts in PKU will share and discuss the projected benefits for PKU patients of a medical food providing a prolonged release of amino acids (AA) allowing an efficient utilization of AAs.
The Satellite Symposium, chaired by Prof. Francjan Van Spronsen and Prof. Alberto Burlina and involving Prof. Rani Singh, Dr. Julio César Rocha, Prof. Anita Mac Donald, will offer the opportunity to learn about the distinctive features of APR Phe-free medical food for PKU management and the patented technology behind it – Phyisiomimic™ Technology, whilst being introduced to scientific data (preclinical and kinetics in human subjects) underpinning the company innovation.
In addition, during the congress, new pre-clinical data supporting the potential of APR’s innovative AA formulation to modulate the trend of some metabolic markers in the same direction as dietary proteins (“Preliminary indications of metabolic modulation by provision of amino acids engineered to allow physiological absorption”) will be presented in a poster.
As confirmed by a recent international market research, management of PKU still represents a challenge for clinicians, patients and families who depend to varying degrees on a restricted long-life dietary regimen and AA supplementations. Innovative solutions that improve the efficiency of AA utilization and control better the Phe levels fluctuations, while maintaining normal energy intake, are a real existing need.
APR Phe-free Medical Food, powered by the patented Physiomimic™ Technology, has been specifically engineered to allow a physiological absorption of amino acids, mimicking that of dietary proteins. Its advanced formulation has the potential to contribute to the maintenance of PHE levels within the recommended ranges, with less prominent fluctuations of PHE levels over time, thus meeting one of the most significant healthcare professionals’ concerns. The applied patented technology, on the other hand, is able to mask taste and odor of free amino acids, by creating a product that can be easily accepted by patients in order to obtain a better and lasting compliance to the dietary treatment.
“We are extremely pleased to have the honor to take part to this important event and to offer to patients and healthcare professionals a new option for PKU management, which marks an important milestone for our company: being a player in the inherited metabolic diseases arena. ” said Giorgio Reiner, Corporate Director R&D of APR ”Starting from PKU unmet clinical and nutritional needs, we leveraged our extensive know-how in pharmaceutical technologies to develop a Medical Food which aims at delivering significant and tangible benefits for a better quality of life.”
Throughout the lifetime of the event, APR will be available at its booth in the Exhibition Area, where it will be possible to get to know the company innovation, gather information and interview the company staff.
About Phenylketonuria or PKU
Phenylketonuria or PKU is a rare, genetic, recessive metabolic disorder affecting about 50.000 people worldwide. PKU is characterized by the deficiency or the malfunctioning of a liver enzyme needed to process phenylalanine (“Phe”), an essential amino acid found in most protein-containing food. Excessive amounts of Phe in the bloodstream become toxic to the brain, impairing the normal development of the central nervous system. If not properly treated, PKU leads to severe, non-recoverable mental retardation and major cognitive disabilities. PKU can only be treated through a strict, life-long, low-protein (low-Phe) dietetic treatment combined with a daily assumption of low-protein modified foods and medical food, which provides Phe-free amino acids and other important nutrients, needed due to the dietary restrictions of PKU patients.
About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR’s business model is currently focused on two pillars: (i) internally developed and financed (alone or together with co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets, combined with a compelling pipeline of products at different stages of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis.
For more information about Physiomimic™ Technology, please visit: www.apr.ch/apr-pharmaproducts/medical-prescription/genetic-metabolic-disease/
APR Applied Pharma Research s.a.:
Paolo Galfetti, +41 91 6957020
Chief Executive Officer
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Age Matters: PMI Calls All Tobacco and E-Cigarette Companies To Do Their Part to Guard Against Youth Nicotine Use23.4.2019 17:29:00 CEST | Pressemelding
Philip Morris International Inc. (PMI) (NYSE: PM) today reaffirmed its vision for the future: To achieve a smoke-free world; that is, one without cigarettes. For the hundreds of millions of men and women globally who will otherwise continue to smoke, PMI’s goal is to switch them to nicotine-containing products that are scientifically substantiated as better choices than continuing to smoke. Our strong belief—if you don’t smoke, don’t start—begins with a continued and robust focus on preventing youth from beginning to smoke or use nicotine products. “Given the rapid pace of innovation in the tobacco products space, we are emphatic that youth should not use any tobacco- or nicotine-containing product. Nicotine is addictive. It is not risk-free, and it poses particular risks for adolescents. We know that great care must be taken to achieve our smoke-free goal. Youth should not become nicotine users. Former smokers and never smokers should not return to, or pick up, the tobacco or nicotine
Personalis, Inc. to Present at European NeoAG Summit 201923.4.2019 15:00:00 CEST | Pressemelding
Personalis, Inc., a leader in advanced genomics for cancer, today announced that the company will present at European NeoAG Summit 2019 in Amsterdam on April 24th at 2:30 PM CEST. The presentation, entitled “ImmunoID NeXT Platform: Improving Neoantigen Prediction, TME Assessment, and ctDNA Detection for Vaccine Development,” will introduce Personalis’ new universal cancer immunogenomics platform, ImmunoID NeXT™. In addition to an overview, the presentation will highlight innovative genomics methods for more comprehensive assessment of neoantigens, which include improving neoantigen-to-MHC binding prediction and ranking and assessing TME/TCR and tumor escape mechanisms that may impact vaccine response. ImmunoID NeXT is the first platform to provide comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays i
Keio Plaza Hotel Tama Opens My Melody, Little Twin Stars Rooms on June 15, 2019 - Sweet Dreams in Our Hello Kitty and Sanrio Character Rooms23.4.2019 14:05:00 CEST | Pressemelding
The Keio Plaza Hotel Co., Ltd., one of Japan’s most prestigious hotel companies operating hotels located in the Shinjuku district of Tokyo and other locations, is proud to announce the strengthening of its collaborative relationship with Sanrio Co., Ltd. (Headquarters: Shinagawa, Tokyo, President and CEO: Shintaro Tsuji) to expand facilities and services featuring “Hello Kitty” and other Sanrio characters at our Keio Plaza Hotel Tama. Our Tama Hotel will renovate a total of four additional rooms, including two rooms each in the themes of “My Melody” and “Little Twin Stars” (Kiki and Lala) who have been adored by fans around the world since their creation in 1975, to be opened on Saturday June 15, 2019, and thereby become the world’s first hotel to operate rooms in these themes on a regular basis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190423005311/en/ New Sanrio characters rooms, including two rooms each in the theme
Project Management Institute, Inc. (PMI) Delivers Full Suite of Certification Exams in Over 5,000 Locations Through Expanded Testing Agreement with Pearson VUE23.4.2019 14:00:00 CEST | Pressemelding
Project Management Institute, Inc. (PMI), the leading not-for-profit professional membership association for the project management profession, and Pearson VUE, a global leader in the computer-based testing industry, have announced an expanded, multi-year agreement that will offer more testing options for candidates looking to earn PMI certifications at all stages of their career. The new agreement will offer candidates access to even more PMI certification tests as well as more flexibility in their testing location options, thanks to Pearson VUE’s global network of testing centers and online proctoring solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190423005149/en/ Beginning July 1, 2019, seven additional PMI programs, including the Project Management Professional (PMP)® – renowned as the global gold standard for project management professionals – will become available to professionals around the globe through Pe
Andersen Global Marks Growth to 50 Countries with Collaborating Firm in Zambia23.4.2019 13:30:00 CEST | Pressemelding
Andersen Global announced it achieved a new milestone today in its continuing growth with the addition of Mulenga Mundashi Kasonde Legal Practitioners (MMKLP). MMKLP, a law firm in Zambia, has signed a Collaboration Agreement with Andersen Global. The international association now has presence in 50 countries through its member and collaborating firms. Led by five partners, MMK has been advising clients in corporate mergers and acquisitions, tax, litigation, and labor and industrial resolutions since 1999. The firm is now one of the largest law firms in Zambia in its twentieth year. The collaborating firm will be the eleventh location in Africa for Andersen Global. “We’ve had the opportunity to advise on some of the highest profile financial events for Zambia in modern history,” said Micheal Mundashi, MMKLP Managing Partner. “One of the things that keeps us moving forward is the desire to provide even more for our local and international clients. Collaborating with Andersen Global will
Aventri Introduces Uber Vouchers to Deliver New Transportation Options23.4.2019 13:00:00 CEST | Pressemelding
Event management software (EMS) leader Aventri today announces a new partnership with Uber for Business. Aventri is the first EMS provider to launch a partnership with Uber for Business to offer customers the opportunity to utilize Uber Vouchers. Uber Vouchers’ web-based tool allows event organizers to provide VIP treatment to attendees with stress-free, reliable transportation to and from events. “We’re always looking for new partners to help our customers streamline events and add value,” said Brad Langley, vice president of channel and partner management for Aventri. “Uber for Business fits the bill. Using Uber Vouchers, organizers spend less time arranging logistics for moving groups, and their guests can come and go at a time that’s convenient for them.” Using Uber Vouchers, organizers can enhance the journey for themselves and their guests. Some benefits include: Customized Control: Organizers can easily create and manage campaigns online by setting parameters for pickup, drop-of